TITLE

Isis Starts Clinical Trials for Hepatitis C Drug

AUTHOR(S)
Webb, Marion
PUB. DATE
April 2002
SOURCE
San Diego Business Journal;4/1/2002, Vol. 23 Issue 13, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports the clinical trials for an experimental hepatitis C drug by Isis Pharmaceuticals Inc. and Elan Corp. in Carlsbad, California. Evaluation on the safety and tolerance of the compound; Details of the drug administration on patients; Views of F. Andrew Dorr, vice president of Isis on drug development.
ACCESSION #
6534862

 

Related Articles

  • Morphine Oral - Elan Corporation: Avinzaâ„¢.  // Drugs in R&D;2002, Vol. 3 Issue 3, p208 

    Adis Comments Elan Corporation is developing an oral, once daily, controlled-release formulation of morphine sulphate (formerly called Morphelanâ„¢) for use in pain management therapy. Elan Corporation has been granted marketing approval by the FDA for Avinzaâ„¢ (morphine sulphate...

  • Elan's New Drug Reduces Severity of Cervical Dystonia.  // Worldwide Biotech;Dec99, Vol. 11 Issue 12, p2 

    Looks at the results of the studies conducted by Elan Pharmaceuticals Inc. of South San Francisco, California on the drug treating cervical dystonia. Evaluation of Elan's Botulinum Toxin Type B Injectable Solution; Phases of the clinical trial; Effectiveness.

  • Corrections & Clarifications.  // BioWorld Today;3/ 6/2013, Vol. 24 Issue 43, p2 

    A correction to the article regarding the 100 percent response rate shown by interim data with the Medivir/Gilead hepatitis C drug that was published in the March 5, 2013 issue is presented.

  • EASL Roundup.  // BioWorld Today;4/20/2012, Vol. 23 Issue 77, p7 

    The article reports that Phase II study of Abbott's direct-acting antivirals in hepatitis C (HCV) has indicated more than 90 percent of patients new to HCV treatment achieved sustained viral response through 12 weeks (SVR12).

  • RNA Silencing Strategy Targets Cholesterol and Hepatitis C. Sheridan, Cormac // BioWorld International;4/2/2008, Vol. 13 Issue 14, p1 

    The article focuses on the clinical trial that will be held in Denmark. According to the author, the trial is centered on the assessment of the safety of a treatment of hepatitis C virus (HCV). According to studies published in "Nature" in March 28, 2008, the process of this treatment involves...

  • High coffee intake associated with better HCV treatment response. DeNyse, Ashley // Infectious Disease News;Jul2011, Vol. 24 Issue 7, p12 

    The article focuses on the findings of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial which revealed the association of increased coffee intake with an improved virologic response to peginterferon/ribavirin treatment in patients with hepatitis C virus infection.

  • Hepatitis C patients needed for clinical trials.  // Hudson Valley Business Journal;11/06/2000-11/13/2000, Vol. 11 Issue 18, p32 

    Announces that Harris, New York-based Community General Hospital is enrolling patients diagnosed with hepatitis C in a clinical trial to evaluate the effectiveness of various treatment regimens for the disease. Contact information.

  • Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics. Rowan, Sarah E.; Rogers, Maya; Bayer, Joshua; Smith, Lisa; Gardner, Edward M.; Johnson, Steven; Langness, Jacob // Clinical Infectious Diseases;10/1/2016, Vol. 63 Issue 7, p994 

    A letter to the editor is presented in response to the article "How generalizable are the results from trials of direct acting antiviral agents to treat people coinfected with HIV/hepatitis C in the real world?," by S. Saeed and colleagues in the 2016 issue.

  • Clinic Roundup.  // BioWorld Today;8/31/2012, Vol. 23 Issue 170, p8 

    The article reports on the initiation of a Phase II trial of oral ELND005 by Elan Corp. plc, the licensing partner of Transition Therapeutics Inc., as an adjunctive maintenance treatment of bipolar I disorder patients to delay the time to occurrence of mood episodes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics